AgeX Therapeutics Reports New Direct Financial Obligation
Ticker: SER · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Agex Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $500,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: debt, financial-obligation, 8-K
TL;DR
**AgeX Therapeutics just took on new debt, watch for financial impact.**
AI Summary
AgeX Therapeutics, Inc. (AGE) filed an 8-K on January 19, 2024, reporting a new direct financial obligation that occurred on January 16, 2024. This filing indicates the creation of a new debt or similar financial commitment, which could impact the company's financial health and future liquidity. Investors should be aware that new financial obligations can increase a company's risk profile and potentially dilute shareholder value if the obligation leads to future equity financing.
Why It Matters
This filing signals a new financial commitment for AgeX Therapeutics, which could affect its balance sheet, cash flow, and overall financial stability, potentially impacting its stock valuation.
Risk Assessment
Risk Level: medium — The creation of a new financial obligation introduces additional risk to the company's financial health, though the specific terms and amount are not disclosed in this filing.
Analyst Insight
Investors should monitor future AgeX Therapeutics filings (like 10-K or 10-Q) for specific details regarding the nature, amount, and terms of this new financial obligation to assess its potential impact on the company's financial health and valuation.
Key Players & Entities
- AgeX Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 16, 2024 (date) — date of the earliest event reported
- January 19, 2024 (date) — date the 8-K was filed
FAQ
What is the primary purpose of this 8-K filing by AgeX Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report the 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant' as per Item 2.03, with the earliest event reported on January 16, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 16, 2024.
What is the trading symbol and exchange for AgeX Therapeutics, Inc. common stock?
The common stock of AgeX Therapeutics, Inc. trades under the symbol 'AGE' on the NYSE American exchange.
What is AgeX Therapeutics, Inc.'s state of incorporation and IRS Employer Identification No.?
AgeX Therapeutics, Inc. is incorporated in Delaware and has an IRS Employer Identification No. of 82-1436829.
Does this 8-K filing provide specific details about the nature or amount of the new financial obligation?
No, this 8-K filing, as provided, only states the 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement' but does not disclose specific details such as the amount, terms, or counterparty of the obligation.
Filing Stats: 624 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-01-19 16:05:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AGE NYSE American Check
- $500,000 — strant On January 16, 2024, AgeX drew $500,000 of its credit available under the Amend
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-003057.txt ( ) — 207KB
- age-20240116.xsd (EX-101.SCH) — 3KB
- age-20240116_lab.xml (EX-101.LAB) — 33KB
- age-20240116_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGEX THERAPEUTICS, INC. Date: January 19, 2024 By: /s/ Andrea E. Park Chief Financial Officer